Japanese BAY88-8223 Monotherapy Phase II Study

A Single-arm, Open-label, Multicenter, Phase II Study of BAY88-8223 in the Treatment of Japanese Patients With Symptomatic Castration-resistant Prostate Cancer (CRPC) With Bone Metastases

To evaluate the efficacy and safety of the best standard of care plus BAY88-8223 in Japanese patients with CRPC and bone metastases after a multiple administration

Inclusion Criteria:

• Have received docetaxel or not eligible for the first course of docetaxel, i.e. patients who are not fit enough and willing.
• Histologically or cytologically confirmed adenocarcinoma of the prostate
• Multiple bone metastases
• Either regular (not occasional) analgesic medication use for cancer-related bone pain or treatment with external beam radiotherapy (EBRT) for bone pain.
• Best standard of care(BSoC) is regarded as the routine standard of care.

Exclusion Criteria :

• Treatment with cytotoxic chemotherapy within previous 4 weeks, or planned during the treatment period
• History of visceral metastasis, or presence of visceral metastasis